Once-weekly Subcutaneous Administration of Bortezomib in Patients with Multiple Myeloma |
Wang, Liang
(Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
Wang, Ke-Feng (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) Chang, Bo-Yang (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) Chen, Xiao-Qin (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) Xia, Zhong-Jun (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine) |
1 | Avet-Loiseau H, Leleu X, Roussel M, et al (2010). Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol, 28, 4630-4. DOI |
2 | Badros A, Goloubeva O, Dalal J S, et al (2007). Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 110, 1042-9. DOI |
3 | Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF (2013). Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood, 121, 884-92. DOI |
4 | Bringhen S, Larocca A, Rossi D, et al (2010). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 116, 4745-53. DOI |
5 | Chanan-Khan A A, and Giralt S (2010). Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol, 28, 2612-24. DOI ScienceOn |
6 | Durie B G, Harousseau J L, Miguel J S, et al (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-73. DOI |
7 | Engelhardt M, Kleber M, Udi J, et al (2010). Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma, 51, 1424-43. DOI |
8 | Harousseau J L, Attal M, and Avet-Loiseau H (2009). The role of complete response in multiple myeloma. Blood, 114, 3139-46. DOI |
9 | Kapoor P, Kumar S K, Dispenzieri A, et al (2013). Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol, 31, 4529-35. DOI |
10 | Knopf KB, Duh MS, Lafeuille MH, et al (2014). Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk, 14, 380-8. DOI |
11 | Koh Y, Lee S Y, Kim I, et al (2014). Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol, 74, 653-7. DOI |
12 | Moreau P, Pylypenko H, Grosicki S, et al (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol, 12, 431-40. DOI |
13 | Kumar SK, Rajkumar SV, Dispenzieri A, et al (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-20. DOI |
14 | Lu J, Lu J, Chen W, et al (2014). Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J, 4, 239. DOI |
15 | Mateos M V (2010). Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev, 36, 24-32. DOI ScienceOn |
16 | Morgan GJ (2013). Transplants for the elderly in myeloma. Blood, 122, 1332-4. DOI |
17 | Nooka AK, Kaufman JL, Behera M, et al (2013). Bortezomibcontaining induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer, 119, 4119-28. DOI |
18 | Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson K C (2009). Multiple myeloma. Lancet, 374, 324-39. DOI |
19 | Reeder CB, Reece DE, Kukreti V, et al (2010). Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-7. DOI |
20 | Richardson PG, Briemberg H, Jagannath S, et al (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 24, 3113-20. DOI ScienceOn |
21 | Sonneveld P, Schmidt-Wolf I G, van der Holt B, et al (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol, 30, 2946-55. DOI |
22 | Richardson PG, Delforge M, Beksac M, et al (2012). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26, 595-608. DOI |
23 | Roschewski M, Korde N, Wu SP and Landgren O (2013). Pursuing the curative blueprint for early myeloma. Blood, 122, 486-90. DOI |
24 | Sonneveld P, Goldschmidt H, Rosinol L, et al (2013). Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol, 31, 3279-87. DOI |
25 | Voorhees P M, Laubach J, Anderson K C and Richardson P G (2013). Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood, 121, 858. DOI |
26 | Wang A, Duan Q, Liu X, et al (2012). (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/ thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol, 91, 1779-84. DOI |